News

you can find more news on our LinkedIn page

05.05.2022

Actome has released the first commercial products to the EU market based on the Protein Interaction Coupling (PICO) Technology. The PICO assay kits for measuring proteins and protein interactions are available through the online webshop .

Actome GmbH is a life-science startup form Freiburg adapting digital PCR (dPCR) technology for the ultra-sensitive measurement of proteins and protein interactions. Our first products based on the Protein Interaction Coupling (PICO) Technology enable the use of the QIAcuity dPCR product line of QIAGEN for measuring proteins and protein interactions. The assay kits contain all necessary materials for labeling of antibodies with the unique PICO Labels and to prepare the assay for readout by dPCR. Registered customers can use the Actome’s AMULATOR software free of charge to analyze proteins and protein interactions with hitherto unseen performance.

01.02.2022

Two of our portfolio companies, traceless materials and FibreCoat GmbH are among the Top 50 Start-ups 2021 in Germany.

FibreCoat could improve from rank 43 in 2020 up to rank 17 in 2021 and traceless leads the ranking. Congratulations to the founders and their teams! (further information)

Our newest portfolio member FibreCoat and its production partner Deutsche Basalt Faser GmbH (DBF) received the approval of a 1.73 mio € grant from the German state of Saxony-Anhalt to expand its production capacity at the DBF site located at Sangerhausen. (further information)

Futhermore, the Lufthansa Group announced its cooperation with the traceless materials GmbH. With help of the start-up, Lufthansa will provide sustainable packaging solutions for its on-board meals which will be fully compostable under natural conditions. (further information)

We are looking forward to futher potentially upcoming good news this week!

14.01.2022

Why 3D bioprinting? Because it is the future of tissue and organ reproduction for transplantation!

How can this goal be achieved and when will there be functioning organs on demand? The article in Frankfurter Rundschau provides an overview of the current situation and the role of 3D bioprinting. Among other industry and thought leaders such as Swedish visionary Erik Gatenholm, Cellbricks with founder Dr. Lutz Kloke is mentioned as Berlin's spearhead of 3D bioprinting.

Moreover, the article demonstrates the reputation of the founders of our portfolio companies since In the same article, Dr. Peter Koltay, CEO of our Freiburg portfolio company Actome GmbH and senior scientist at the Institute for Microsystems Technology (IMTEK) at the University of Freiburg, comments on the state of development and the potential of the technology. Actome GmbH und leitender Wissenschaftler des Instituts für Mikrosystemtechnik (IMTEK) an der Universität Freiburg, ordnet im gleichen Artikel den Entwicklungsstand und die Potenziale der Technologie als Experte ein.

Frankfurter Rundschau article.

07.01.2022

Actome and QIAGEN have signed a licensing and co-marketing agreement to jointly accelerate the commercialization of Actome’s proprietary Protein-Interaction-Coupling (PICO) -Technology

Actome GmbH, a life-science start-up company from the University of Freiburg and Hahn-Schickard, Germany has signed a license agreement and a co-marketing agreement with QIAGEN GmbH, Hilden, Germany, to jointly accelerate the market entry of Actome’s Protein-Interaction-Coupling (PICO) - Technology. The collaboration will help Actome to bring products to the market faster while providing a unique innovative feature to the QIAcuity dPCR product line of QIAGEN. Actome will market first products exclusively for use on QIAGEN’s digital PCR instruments as well as support QIAGEN in developing own products. Both partners will jointly commercialize the disruptive PICO-Technology for molecular biological research in the future.

The unique performance of Actome’s products is based on the patented PICO -Technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA- barcodes. These barcodes are then detected by the method of digital PCR and decoded by a proprietary software developed by Actome. “Our PICO-Technology expands the capabilities of the QIAcuity digital PCR platform by QIAGEN from nucleic acids to proteins. The application of our technology in the fields of proteomics, molecular pathway research and biomarker discovery will help to increase our knowledge about molecular biological processes and will transform molecular biological research in an unprecedented way.” says Csaba Jeney, co-founder, CEO, and inventor of the technology.

Proteins control and direct biological processes through their interactions, the so-called interactome, by which they determine our health and wellbeing. Tools to study the interactome enable the understanding of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling these challenges, Actome's innovative technology is a breakthrough that will revolutionize research and biomedicine. “QIAcuity is expanding into new research fields as a cost-effective and very reliable digital PCR system,” said Thomas Schweins, Senior Vice President, Head of the Life Science Business Area at QIAGEN. “The partnership with Actome extends the use of this technology to protein quantification and protein-protein interaction.”

Actome GmbH is a privately held young life-science startup founded in 2017. The year before Dr. Jeney moved from Budapest to Freiburg to partner with Dr. Koltay and to leverage his start-up experience and the excellent environment provided by the University of Freiburg and the Hahn-Schickard research institute in Freiburg. Actome provides assay kits, bioinformatics software and services for the sensitive, highly parallel and quantitative measurement of proteins and protein interactions. The long term vision of Actome is to decode the whole interactome and to exploit these discoveries in molecular diagnostic products for personalized medicine. Actome’s first products will target the research market in the field of molecular biology with a specific focus on assay-kits for multi-omics and single cell analysis.

www.actome.de

QIAGEN press release

10.01.2022

SenseUp has been awarded a grant by the Federal Ministry of Education and Research (BMBF), for SenseUp to apply their platform technology to the production of pharmaceutical proteins and peptides. The grant provides SenseUp with 2,1 million € non-dilutive funding and will be used to further develop and scale-up their bio-production platform for pharmaceutical proteins and peptides in the next 5 years.

The funding was provided as part of the project "ModellRegion, BioRevierPLUS: BioökonomieREVIER ". With this project, the BMBF is funding a wide variety of promising research, development, and innovation projects (R&D&I) in the field of the bioeconomy in the Rheinischen Revier as part of the National Bioeconomy Strategy and the Structural Strengthening of Coal Regions Act.

SenseUp sees this funding success as a confirmation of their bio-production strategy and the great potential of bio-manufacturing determining what we eat, what cures us, the products we put on our skin, and the way we build our physical world in the coming decades. The company will play a key role in this transformation by enabling efficient bio-production platforms with crucial cost- and scaling-advantages using its disruptive natural evolution technology.

"SenseUp has a unique advantage here'' says Dr. Georg Schaumann, CEO and founder of the company, ''we have already developed groundbreaking bio-production processes for fine chemicals using our unique natural evolution technology. With this grant, we will now be able to do the same for pharmaceutical proteins and peptides."

About SenseUp Biotechnology GmbH
Founded in 2015, SenseUp develops microbial production strains and processes for large-scale production of e.g. amino acids under a licensing model. Compared to conventional optimization strategies, the patented SenseUp technology allows for 50,000 times faster selection of optimized production strains under relevant process conditions and thus enables customized and process-specific development of ready-to-use and optionally GMO-free high-performance production organisms. Especially for food and feed applications, these are important advantages for SenseUp customers. Extending the product-spectrum to RNA and proteins/peptides, SenseUp additionally focusses on markets for pharmaceuticals, animal-free consumer products and biopesticides.

17.11.2021

Aachen 21.10.2021 - FibreCoat GmbHan innovative composite materials spin-off from the Institut für Textiltechnik (ITA) of RWTH Aachen, announces it closed a $3 million Series A round with Goose Capital, Phoenix Venture Partners, b.value AG, NOVA by Saint-Gobain and the TiE Houston Angels, led by Ashok Rao (Goose Capital). The capital raised is being used to expand the FibreCoat team to increase sales and marketing activities as the company looks to increase capacity and to allow FibreCoat to build new partnerships in the construction, electronics, and automotive industry.

These strong investors offer a knowledgeable background in materials and a diverse network into the markets we serve as we lay the foundation for scaling our technology to increase our capacity from 10 tons per month by the end of 2021 to 60 tons per month in 2022” said Robert Brüll, CEO, FibreCoat.

FibreCoat offers a revolutionary coating technology for fibres in composite and shielding applications as a basic building block for tomorrow's mobility and construction industries. Developed by co-founders Robert Brüll, Alexander Lüking, and Richard Haas as part of their doctoral studies at the RWTH Aachen University (Germany), FibreCoat’s product lines include AluCoat, metal-coated basalt fibres used for electromagnetic shielding and conducting applications, and PolyCoat, thermoplastic-coated glass fibres used for strengthening and light weighting applications. The coated fibres provide substantial quality advantages due to the single-filament coating and the tunability of the materials (e.g., adjustable coating thickness, homogeneity, thin core fibres). FibreCoat produces application- and customer-specific bicomponent filaments for a wide range of applications resulting in disruptive advances in the composite and EMI shielding industries. It provides a significant advantage over other technologies due to its high speed and one-step technology process, with substantial-quality advantages resulting from the single-fibre coating. The high-performance fibres not only improve existing products but enable completely new mass market applications in areas ranging from light-weight EMI shielding in electric vehicles and defence applications to drape-able EMI shielding fabrics for smart textiles or wallpapers in hospitals.

In addition to high-coating flexibility, our extensive network for customer-specific processing of coated fibres differentiates us from our competitors” said Brüll. “Our first market-ready product, AluCoatsaves up to 90 percent in CO2 emissions during production when compared to alternative materials, such as solid metal fibres, and aluminium foils and sheets, while also being fully recyclable.“

The Series A funding was a result of FibreCoat’s outstanding technology and performance at this year’s Rice Business Plan Competition (RBPC), where the company was represented as the TiE Global automatic European entry after successfully winning TiE Global’s feeder competition in Europe. As the largest intercollegiate start-up competition in the world, RBPC provided the perfect combination with TiE for FibreCoat to leverage an extensive network, placing third in the final competition. The RBPC invites start-ups from 42 top universities from around the world to compete at the Jones Graduate School of Business at Rice University each spring in front of over 300 investors and other judges for over $1.5 million in prize money. Past RBPC alumni have raised more than $3.5 billion in funding.This achievement attracted the attention of Goose Capital, which led to the success of this round” added Brüll.

Goose Capital began 15 years ago as a small group of successful executives committed to supporting emerging entrepreneurs and has evolved into a professional investment organization providing capital, mentorship, and board members to early-stage companies. Members of Goose Capital have broad experience across multiple industry sectors. Goose Capital has invested over $50 million in start-ups, and currently has around twenty companies in its portfolio. Goose Capital provides the Grand Prize at the Rice Business Plan Competition and often provides much more, having invested over $20 million in RBPC winners alone.We are thrilled to be part of this incredible competition, delivering high quality teams to Rice, from Universities in Europe and Asia”, said Ashok Rao, past Chairman of TiE Global and the founder of this feeder competition program along with Brad Burke, Managing Director of the Rice Alliance.“ Our teams from Europe and Asia have acquitted themselves admirably for the 10 years this program has been in existence with 4 teams having made it the finals while obtaining over $10 million in investment from Goose.” And in his role of Board Director of Goose Capital and future Chairman of the Board of Directors of FibreCoat, Rao added “FibreCoat is an exciting investment opportunity for our Goose members. The interest level was so high that this offering was oversubscribed by 200%.“ https://www.goose.capital/

The b.value team has more than 40 years of experience in setting up, leading, and developing technology companies and commercializing biotechnological developments. Their investment philosophy focuses on talented entrepreneurs who want to create a passionate company with knowledge and courage from a business model with high scalability and disruptive proprietary technology. “We are very proud to welcome FibreCoat with their ground-breaking composite fibres to our portfolio. We believe that FibreCoat will revolutionize the composites market in the coming years, and b.value AG is delighted to be part of this journey,” said Georg Lentzen, Managing Director, b.value. www.b-value.de.

Phoenix Venture Partners (PVP) invests at the convergence of advanced materials, biology and hardware with advanced computation and AI. PVP employs a multi-stage investment strategy, encompassing both seed and venture investment programs, and assists entrepreneurs with customer and supply chain business development. https://phoenix-vp.com/

NOVA by Saint-Gobain, the corporate venturing arm of Saint-Gobain, acts as a bridge by working with qualified start-ups by providing access to Saint-Gobain's internal resources and helping start-ups form long-term partnerships. Rooted in trust, expertise, support, and flexibility, the NOVA team supports entrepreneurs whose focus aligns with their expertise to create a path to market. “Our partnership with FibreCoat will bring innovative solutions to our customers and aligns well with our mission of making the world the better home,” said Minas Apelian, Vice President, Internal and External Venturing, Saint-Gobain. https://www.nova-saint-gobain.com/

The mission of the TiE Houston Angels is to foster entrepreneurship through mentoring, networking, education, funding, and incubation. With a focus on giving back to the community, TiE’s focus is on generating and nurturing the next generation of entrepreneurs. The overall aim is to empower individuals and create wealth in communities by assisting entrepreneurs. https://houston.tie.org/ 

FibreCoat is interested to connect with anyone interested in affordable conductive fibres and would like to reach out to info@fibrecoat.de or visit www.fibrecoat.de.

About FibreCoat GmbH

FibreCoat GmbH is a start-up company based in Aachen, Germany, offering a revolutionary coating technology for coated fibres in composite and shielding applications as a basic building block for tomorrow's mobility and construction industries. To make high-performance materials affordable for high-volume production, FibreCoat focuses on continuous innovation and strong partnerships. Learn more at https://www.fibrecoat.de/.

21.10.2021

The female-founded start-up traceless materials that developed a holistically sustainable alternative material for plastic, receives a €2.42million grant and equity investment from the European Innovation Council (EIC). The funding will allow traceless to bring its novel naturally compostable biomaterial to market, substituting plastic and bioplastic in products that can easily end up in the environment - solving global plastic pollution. 

Since its founding in September 2020 traceless has shown clear ambitions to bring their materials to market fast. The continuously growing team is developing several prototypes, among others an e-commerce shipping bag with OTTO (https://www.otto.de/newsroom/de/kundenfokus/kampf-gegen-plastikmuell-wie-traceless- die-welt-aufraeumen-will), one of Europe's biggest e-commerce companies. Simultaneously, a successful seed investment allowed traceless materials to build its first pilot production plant to realize first market pilots. The company will use the EIC funding to further accelerate its scale up through the building of a demonstration production plant which will enable a first market entry for traceless materials. 

The EIC evaluation committee praises the excellence of traceless’ invention: “The proposed innovation represents a true breakthrough in the field of plastic materials as it combines a circular and sustainable approach, based upon agricultural waste, innovative transformation steps, and final characteristics of the materials, which are beyond the state of the art and will bring a fully biodegradable solution in many sectors. The combination of biodegradability with specific thermomechanical, barrier and compatibility properties, can generate relevant market opportunities, especially from the packaging industry.”

Learn more about traceless materials and read the official press release.

13.10.2021

We warmly welcome back our new and former team member Pelin Yilmaz! Pelin, we are excited to work with you again benefiting from your deep tech expertise, your passion for innovations, and your power.

Besides her expertise in bioinformatics, microbiology and marine biology, Pelin will bring in her new understandings of microbiome in human health from her last job. She augments the women power of our team to foster the expansion of b.value’s portfolio.

01.07.2021

Actome GmbH, a life‐science start‐up company from the University of Freiburg and Hahn‐Schickard, Germany has closed a seed investment agreement with b.value AG, Düsseldorf, Germany and further investors. The seed investment will be used to establish the operative business and to bring Actome’s first commercial products to the market. The first in class products will support life science researchers by enabling the quantification of proteins and protein interactions in biological samples with hitherto unseen sensitivity and specificity.

The unique performance of Actome’s products is based on the patented "Emulsion Coupling" technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA‐barcodes. These barcodes are then detected by the method of digital PCR and decoded by a proprietary software developed by Actome. “Our technology expands the capabilities of digital PCR from nucleic acids to proteins. The application of our technology in the fields of proteomics, molecular pathway research and biomarker discovery will help to increase our knowledge about molecular biological processes and will transform medical diagnostics in an unprecedented way.” says Csaba Jeney, co‐founder, CEO, and inventor of the technology.

Proteins control and direct biological processes through their interactions, the so‐called interactome, by which they determine our health and wellbeing. Tools to study the interactome enable the understanding of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling these challenges, Actome's innovative technology is a breakthrough that will revolutionize research and biomedicine. The managing director of b.value AG, Peter Kallien, is excited about these opportunities: “This is why Actome fascinated us from the first moment on. We have been impressed how the team developed an extraordinary precise technology with huge benefits for proteomics research, which will allow to define better diagnostic biomarkers and therapies.”

In addition to the investment, b.value AG will actively support Actome’s business development in the future to increase outreach and accelerate growth. Further continued support by the University of Freiburg, Hahn‐Schickard, BadenCampus, Life‐science Accelerator Baden‐Württemberg, bwcon and Science4life is gratefully acknowledged by Actome.

About Actome GmbH

Actome is a privately held young life‐science startup founded in 2017. The year before Dr. Jeney moved from Budapest to Freiburg to partner with Dr. Koltay and to leverage his start‐up experience and the excellent environment provided by the University of Freiburg and the research provider Hahn‐Schickard in Freiburg. Actome provides assay kits, bioinformatics software and services for the sensitive, highly parallel and quantitative measurement of proteins and protein interactions. The long term vision of Actome is to decode the whole interactome and to exploit these discoveries in molecular diagnostic products for personalized medicine. Actome’s first products will target the research market with a specific focus on assay‐kits for multi‐omics and single cell analysis. www.actome.de

About b.value AG

Beyond investing as a seed venture capital provider for biotechnology, life sciences and chemistry, b.value AG actively support their portfolio companies in the development with the unique “b.value Company Building” approach: Portfolio companies benefit from the high level of technological expertise and operational experience of the b.value team. The managing team has more than 40 years of experience in setting up, leading, and developing technology companies and commercializing biotechnological developments. Moreover, they profit from the accumulated experience of b.value ́s supervisory board and broad network. www.b-value.de 

For further information, please contact:

Dr. Peter Koltay, CEO

Phone: +49 761 203 73240 E‐Mail: peter.koltay@actome.de

Contact Person

Dr. Georg Lentzen (Managing Director)

Georg.Lentzen@b-value.de

 

Peter Kallien (Managing Director)

Peter.Kallien@b-value.de

Contact

b.value AG

Otto-Hahn-Straße 15

44227 Dortmund

 

+49 (0) 231/79300196

The industry is looking for technologies.

We are looking for biotechnology investments.

Copyright 2021 b.value AG